Therapeutic	0	11	O
targeting	12	21	O
of	22	24	O
the	25	28	O
survivin	29	37	B-Gene_or_gene_product
pathway	38	45	O
in	46	48	O
cancer	49	55	O
:	55	56	O
initiation	57	67	O
of	68	70	O
mitochondrial	71	84	O
apoptosis	85	94	O
and	95	98	O
suppression	99	110	O
of	111	113	O
tumor	114	119	B-Pathological_formation
-	119	120	O
associated	120	130	O
angiogenesis	131	143	O
.	143	144	O

PURPOSE	146	153	O
:	153	154	O
Molecular	155	164	O
antagonists	165	176	O
of	177	179	O
the	180	183	O
inhibitor	184	193	O
of	194	196	O
apoptosis	197	206	O
protein	207	214	O
survivin	215	223	B-Gene_or_gene_product
have	224	228	O
shown	229	234	O
promise	235	242	O
as	243	245	O
novel	246	251	O
anticancer	252	262	O
strategies	263	273	O
for	274	277	O
triggering	278	288	O
tumor	289	294	B-Cell
cell	295	299	I-Cell
apoptosis	300	309	O
,	309	310	O
dysregulating	311	324	O
mitotic	325	332	O
progression	333	344	O
,	344	345	O
and	346	349	O
inhibiting	350	360	O
tumor	361	366	B-Pathological_formation
growth	367	373	O
in	374	376	O
preclinical	377	388	O
models	389	395	O
.	395	396	O

However	397	404	O
,	404	405	O
how	406	409	O
survivin	410	418	B-Gene_or_gene_product
couples	419	426	O
to	427	429	O
the	430	433	O
cell	434	438	B-Cell
death	439	444	O
machinery	445	454	O
has	455	458	O
remained	459	467	O
elusive	468	475	O
,	475	476	O
and	477	480	O
the	481	484	O
relevant	485	493	O
cellular	494	502	O
targets	503	510	O
of	511	513	O
survivin	514	522	B-Gene_or_gene_product
antagonists	523	534	O
have	535	539	O
not	540	543	O
been	544	548	O
completely	549	559	O
elucidated	560	570	O
.	570	571	O

Experimental	572	584	O
Design	585	591	O
:	591	592	O
Human	593	598	B-Organism
umbilical	599	608	B-Cell
vein	609	613	I-Cell
and	614	617	O
dermal	618	624	B-Cell
microvascular	625	638	I-Cell
endothelial	639	650	I-Cell
cells	651	656	I-Cell
were	657	661	O
infected	662	670	O
with	671	675	O
replication	676	687	O
-	687	688	O
deficient	688	697	O
adenoviruses	698	710	B-Organism
encoding	711	719	O
survivin	720	728	B-Gene_or_gene_product
(	729	730	O
pAd	730	733	B-Gene_or_gene_product
-	733	734	I-Gene_or_gene_product
Survivin	734	742	I-Gene_or_gene_product
)	742	743	O
,	743	744	O
green	745	750	B-Gene_or_gene_product
fluorescent	751	762	I-Gene_or_gene_product
protein	763	770	I-Gene_or_gene_product
(	771	772	O
pAd	772	775	B-Gene_or_gene_product
-	775	776	I-Gene_or_gene_product
GFP	776	779	I-Gene_or_gene_product
)	779	780	O
,	780	781	O
or	782	784	O
a	785	786	O
phosphorylation	787	802	O
-	802	803	O
defective	803	812	O
survivin	813	821	B-Gene_or_gene_product
Thr	822	825	O
(	825	826	O
34	826	828	O
)	828	829	O
-	829	830	O
-	830	831	O
>	831	832	O
Ala	832	835	O
(	836	837	O
pAd	837	840	B-Gene_or_gene_product
-	840	841	I-Gene_or_gene_product
T34A	841	845	I-Gene_or_gene_product
)	845	846	O
dominant	847	855	O
negative	856	864	O
mutant	865	871	O
.	871	872	O

The	873	876	O
effect	877	883	O
of	884	886	O
wild	887	891	O
-	891	892	O
type	892	896	O
or	897	899	O
mutant	900	906	O
survivin	907	915	B-Gene_or_gene_product
was	916	919	O
investigated	920	932	O
on	933	935	O
capillary	936	945	B-Multi-tissue_structure
network	946	953	I-Multi-tissue_structure
stability	954	963	O
,	963	964	O
endothelial	965	976	B-Cell
cell	977	981	I-Cell
viability	982	991	O
,	991	992	O
and	993	996	O
caspase	997	1004	B-Gene_or_gene_product
activation	1005	1015	O
in	1016	1018	O
vitro	1019	1024	O
and	1025	1028	O
on	1029	1031	O
kinetics	1032	1040	O
of	1041	1043	O
tumor	1044	1049	B-Pathological_formation
growth	1050	1056	O
and	1057	1060	O
development	1061	1072	O
of	1073	1075	O
angiogenesis	1076	1088	O
in	1089	1091	O
a	1092	1093	O
breast	1094	1100	B-Pathological_formation
cancer	1101	1107	I-Pathological_formation
xenograft	1108	1117	I-Pathological_formation
model	1118	1123	O
in	1124	1126	O
vivo	1127	1131	O
.	1131	1132	O

The	1133	1136	O
cell	1137	1141	B-Cell
death	1142	1147	O
pathway	1148	1155	O
initiated	1156	1165	O
by	1166	1168	O
survivin	1169	1177	B-Gene_or_gene_product
targeting	1178	1187	O
was	1188	1191	O
mapped	1192	1198	O
with	1199	1203	O
respect	1204	1211	O
to	1212	1214	O
cytochrome	1215	1225	B-Gene_or_gene_product
c	1226	1227	I-Gene_or_gene_product
release	1228	1235	O
,	1235	1236	O
changes	1237	1244	O
in	1245	1247	O
mitochondrial	1248	1261	O
transmembrane	1262	1275	O
potential	1276	1285	O
,	1285	1286	O
and	1287	1290	O
apoptosome	1291	1301	O
requirements	1302	1314	O
using	1315	1320	O
mouse	1321	1326	B-Organism
embryonic	1327	1336	B-Cell
fibroblasts	1337	1348	I-Cell
deficient	1349	1358	O
in	1359	1361	O
Apaf	1362	1366	B-Gene_or_gene_product
-	1366	1367	I-Gene_or_gene_product
1	1367	1368	I-Gene_or_gene_product
or	1369	1371	O
caspase	1372	1379	B-Gene_or_gene_product
-	1379	1380	I-Gene_or_gene_product
9	1380	1381	I-Gene_or_gene_product
.	1381	1382	O

RESULTS	1383	1390	O
:	1390	1391	O
Adenoviral	1392	1402	B-Organism
transduction	1403	1415	O
of	1416	1418	O
endothelial	1419	1430	B-Cell
cells	1431	1436	I-Cell
with	1437	1441	O
pAd	1442	1445	B-Gene_or_gene_product
-	1445	1446	I-Gene_or_gene_product
Survivin	1446	1454	I-Gene_or_gene_product
inhibited	1455	1464	O
growth	1465	1471	O
factor	1472	1478	O
deprivation	1479	1490	O
-	1490	1491	O
or	1492	1494	O
ceramide	1495	1503	B-Drug_or_compound
-	1503	1504	O
induced	1504	1511	O
apoptosis	1512	1521	O
,	1521	1522	O
reduced	1523	1530	O
caspase	1531	1538	B-Gene_or_gene_product
-	1538	1539	I-Gene_or_gene_product
3	1539	1540	I-Gene_or_gene_product
and	1541	1544	O
-	1545	1546	B-Gene_or_gene_product
7	1546	1547	I-Gene_or_gene_product
generation	1548	1558	O
,	1558	1559	O
and	1560	1563	O
stabilized	1564	1574	O
three	1575	1580	O
-	1580	1581	O
dimensional	1581	1592	O
capillary	1593	1602	B-Multi-tissue_structure
networks	1603	1611	I-Multi-tissue_structure
in	1612	1614	O
vitro	1615	1620	O
.	1620	1621	O

Conversely	1622	1632	O
,	1632	1633	O
expression	1634	1644	O
of	1645	1647	O
pAd	1648	1651	B-Gene_or_gene_product
-	1651	1652	I-Gene_or_gene_product
T34A	1652	1656	I-Gene_or_gene_product
caused	1657	1663	O
apoptosis	1664	1673	O
in	1674	1676	O
umbilical	1677	1686	B-Cell
vein	1687	1691	I-Cell
and	1692	1695	O
dermal	1696	1702	B-Cell
microvascular	1703	1716	I-Cell
endothelial	1717	1728	I-Cell
cells	1729	1734	I-Cell
and	1735	1738	O
resulted	1739	1747	O
in	1748	1750	O
caspase	1751	1758	B-Gene_or_gene_product
-	1758	1759	I-Gene_or_gene_product
3	1759	1760	I-Gene_or_gene_product
activity	1761	1769	O
.	1769	1770	O

Cell	1771	1775	B-Cell
death	1776	1781	O
induced	1782	1789	O
by	1790	1792	O
survivin	1793	1801	B-Gene_or_gene_product
targeting	1802	1811	O
exhibited	1812	1821	O
the	1822	1825	O
hallmarks	1826	1835	O
of	1836	1838	O
mitochondrial	1839	1852	O
-	1852	1853	O
dependent	1853	1862	O
apoptosis	1863	1872	O
with	1873	1877	O
release	1878	1885	O
of	1886	1888	O
cytochrome	1889	1899	B-Gene_or_gene_product
c	1900	1901	I-Gene_or_gene_product
and	1902	1905	O
loss	1906	1910	O
of	1911	1913	O
mitochondrial	1914	1927	O
transmembrane	1928	1941	O
potential	1942	1951	O
and	1952	1955	O
was	1956	1959	O
suppressed	1960	1970	O
in	1971	1973	O
Apaf	1974	1978	B-Gene_or_gene_product
-	1978	1979	I-Gene_or_gene_product
1	1979	1980	I-Gene_or_gene_product
or	1981	1983	O
caspase	1984	1991	B-Gene_or_gene_product
-	1991	1992	I-Gene_or_gene_product
9	1992	1993	I-Gene_or_gene_product
knockout	1994	2002	O
mouse	2003	2008	B-Organism
embryonic	2009	2018	B-Cell
fibroblasts	2019	2030	I-Cell
.	2030	2031	O

When	2032	2036	O
injected	2037	2045	O
in	2046	2048	O
human	2049	2054	B-Organism
breast	2055	2061	B-Pathological_formation
cancer	2062	2068	I-Pathological_formation
xenografts	2069	2079	I-Pathological_formation
,	2079	2080	O
pAd	2081	2084	B-Gene_or_gene_product
-	2084	2085	I-Gene_or_gene_product
T34A	2085	2089	I-Gene_or_gene_product
inhibited	2090	2099	O
growth	2100	2106	O
of	2107	2109	O
established	2110	2121	O
tumors	2122	2128	B-Pathological_formation
and	2129	2132	O
triggered	2133	2142	O
tumor	2143	2148	B-Cell
cell	2149	2153	I-Cell
apoptosis	2154	2163	O
in	2164	2166	O
vivo	2167	2171	O
.	2171	2172	O

This	2173	2177	O
was	2178	2181	O
associated	2182	2192	O
with	2193	2197	O
a	2198	2199	O
approximately	2200	2213	O
60	2214	2216	O
%	2216	2217	O
reduction	2218	2227	O
in	2228	2230	O
tumor	2231	2236	B-Pathological_formation
-	2236	2237	O
derived	2237	2244	O
blood	2245	2250	B-Multi-tissue_structure
vessels	2251	2258	I-Multi-tissue_structure
by	2259	2261	O
quantitative	2262	2274	O
morphometry	2275	2286	O
of	2287	2289	O
CD31	2290	2294	B-Gene_or_gene_product
-	2294	2295	O
stained	2295	2302	O
tumor	2303	2308	B-Pathological_formation
areas	2309	2314	O
,	2314	2315	O
and	2316	2319	O
appearance	2320	2330	O
of	2331	2333	O
endothelial	2334	2345	B-Cell
cell	2346	2350	I-Cell
apoptosis	2351	2360	O
by	2361	2363	O
internucleosomal	2364	2380	O
DNA	2381	2384	O
fragmentation	2385	2398	O
in	2399	2401	O
vivo	2402	2406	O
.	2406	2407	O

CONCLUSIONS	2408	2419	O
:	2419	2420	O
Survivin	2421	2429	B-Gene_or_gene_product
functions	2430	2439	O
as	2440	2442	O
a	2443	2444	O
novel	2445	2450	O
upstream	2451	2459	O
regulator	2460	2469	O
of	2470	2472	O
mitochondrial	2473	2486	O
-	2486	2487	O
dependent	2487	2496	O
apoptosis	2497	2506	O
,	2506	2507	O
and	2508	2511	O
molecular	2512	2521	O
targeting	2522	2531	O
of	2532	2534	O
this	2535	2539	O
pathway	2540	2547	O
results	2548	2555	O
in	2556	2558	O
anticancer	2559	2569	O
activity	2570	2578	O
via	2579	2582	O
a	2583	2584	O
dual	2585	2589	O
mechanism	2590	2599	O
of	2600	2602	O
induction	2603	2612	O
of	2613	2615	O
tumor	2616	2621	B-Cell
cell	2622	2626	I-Cell
apoptosis	2627	2636	O
and	2637	2640	O
suppression	2641	2652	O
of	2653	2655	O
angiogenesis	2656	2668	O
.	2668	2669	O

